Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 9/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | SMO | Q99835 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8778780 | 0.93 | TDP1 (0.43) | CYP1A2PDE10ASMOTDP1L3MBTL1 | |
| SCHEMBL8871869 | 0.83 | PDE10A (0.42) | CYP1A2PDE10ASMOL3MBTL1NPC1 | |
| SCHEMBL8778671 | 0.79 | CYP1A2 (0.46) | CYP1A2PDE10AHTR3AHRH4TDP1 | |
| SCHEMBL8515341 | 0.77 | TDP1 (0.49) | CYP1A2PDE10AHTR3AHRH4TDP1 | |
| SCHEMBL8778766 | 0.77 | CYP1A2 (0.42) | CYP1A2PDE10AHTR3AHRH4 | |
| SCHEMBL3792267 | 0.76 | CYP1A2 (0.36) | CYP1A2PDE10AHTR3AHRH4 | |
| SCHEMBL8778865 | 0.75 | CYP1A2 (0.39) | CYP1A2SMONPC1 | |
| SCHEMBL8776938 | 0.74 | PDE10A (0.51) | CYP1A2PDE10ATDP1L3MBTL1NPC1 | |
| SCHEMBL8870416 | 0.74 | CYP1A2 (0.42) | CYP1A2PDE10AHTR3AHRH4TDP1 | |
| SCHEMBL28091206 | 0.73 | CYP1A2 (0.50) | CYP1A2TDP1ARNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129875-A1 | SUBSTITUTED QUINAZOLINES AS FUNGICIDES | SYNGENTA CROP PROTECTION, LLC (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120129875-A1 | SUBSTITUTED QUINAZOLINES AS FUNGICIDES | SYNGENTA CROP PROTECTION, LLC (US) | 2012-05-24 | — | — | US | disclosed |
| WO-2010136475-A1 | SUBSTITUTED QUINAZOLINES AS FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129875-A1 | SUBSTITUTED QUINAZOLINES AS FUNGICIDES | NAT1, NQO2, NOX1 | CYP1A2 18/4885PDE10A 1335/4885HTR3A 2680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.